Long-Term Scleroderma Data Support Cytori's Phase III Plans
This article was originally published in Scrip
Executive Summary
Twelve scleroderma patients experienced long-term improvement of their rare skin disease symptoms after a single administration of the Cytori Therapeutics cell therapy ECCS-50 in an investigator-initiated, open-label study published in the journal Rheumatology on Sept. 8.